Insulet (NASDAQ:PODD) Posts Quarterly Earnings Results, Beats Estimates By $0.19 EPS

Insulet (NASDAQ:PODD) posted its quarterly earnings results on Wednesday. The medical instruments supplier reported $1.66 earnings per share for the quarter, topping the consensus estimate of $1.47 by $0.19, FiscalAI reports. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. During the same quarter in the prior year, the company earned $1.17 EPS. The firm’s quarterly revenue was up 23.5% compared to the same quarter last year. Insulet updated its FY 2026 guidance to 6.460- EPS.

Here are the key takeaways from Insulet’s conference call:

• Strong second-quarter performance: Revenue increased 23% on a constant-currency basis to $802 million, while adjusted operating margin expanded 140 basis points to 19.3% and adjusted EPS rose 41.5% to $1.66.
• Insulet lowered its 2026 outlook to 20%–22% total company revenue growth and 17%–19% U.S. Omnipod growth, citing weaker-than-expected type 2 customer retention and utilization, slower new customer starts, and somewhat lower anticipated pricing.
• The company is expanding customer support, revising sales-force incentives to emphasize retention, refining sampling, and scaling Omnipod Discover to improve onboarding and retention during the critical first 90 days of therapy.
• International momentum remains strong, with full-year international Omnipod growth guidance raised to 30%–32%; the company also reported coverage additions for 6.5 million lives and reduced prior-authorization barriers for approximately 10 million lives.
• Insulet continues to invest in its pipeline, including Omnipod 6 and a fully closed-loop type 2 system, with a 510(k) submission for the latter still expected in 2027; formal 2027 guidance and an updated long-range outlook will come with fourth-quarter results.

Insulet Price Performance

NASDAQ PODD traded up $5.34 during trading hours on Thursday, hitting $138.60. The company had a trading volume of 2,444,539 shares, compared to its average volume of 1,306,391. Insulet has a 52 week low of $126.40 and a 52 week high of $354.88. The firm has a 50 day simple moving average of $155.56 and a 200 day simple moving average of $195.01. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. The firm has a market capitalization of $9.60 billion, a price-to-earnings ratio of 32.14, a PEG ratio of 1.16 and a beta of 1.10.

Insider Buying and Selling at Insulet

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director directly owned 9,041 shares in the company, valued at approximately $1,297,473.91. This represents a 44.63% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 0.36% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Insulet

Several hedge funds have recently bought and sold shares of the company. EFG International AG bought a new stake in Insulet during the 4th quarter worth approximately $54,000. T. Rowe Price Investment Management Inc. boosted its holdings in Insulet by 275.6% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 338 shares of the medical instruments supplier’s stock valued at $97,000 after purchasing an additional 248 shares during the period. Zions Bancorporation National Association UT boosted its holdings in Insulet by 107.5% in the 4th quarter. Zions Bancorporation National Association UT now owns 359 shares of the medical instruments supplier’s stock valued at $102,000 after purchasing an additional 186 shares during the period. GW&K Investment Management LLC grew its position in shares of Insulet by 40.1% during the 4th quarter. GW&K Investment Management LLC now owns 346 shares of the medical instruments supplier’s stock valued at $98,000 after purchasing an additional 99 shares in the last quarter. Finally, Brown Brothers Harriman & Co. grew its position in shares of Insulet by 44.6% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 227 shares of the medical instruments supplier’s stock valued at $70,000 after purchasing an additional 70 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have commented on PODD. Royal Bank Of Canada dropped their price objective on shares of Insulet from $245.00 to $160.00 and set an “outperform” rating on the stock in a report on Thursday. Wall Street Zen raised shares of Insulet from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Oppenheimer cut shares of Insulet from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Benchmark cut their price objective on shares of Insulet from $250.00 to $185.00 and set a “buy” rating for the company in a report on Thursday. Finally, Piper Sandler cut their price objective on shares of Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. Fifteen investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Insulet has a consensus rating of “Hold” and a consensus price target of $201.40.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported second-quarter adjusted earnings of $1.66 per share and revenue of $801.7 million, exceeding analyst estimates of $1.47 and $787.4 million, respectively. Revenue increased 23.5% year over year. Reuters earnings and outlook report
• Positive Sentiment: Management said overall growth remains intact, supported by Omnipod adoption and expansion in the broader insulin-pump market, although the company is resetting expectations for Type 2 customers. Insulet earnings call summary
• Positive Sentiment: Benchmark and Stifel retained “buy” ratings while lowering their price targets to $185 and $180, respectively, implying substantial potential upside from recent levels.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.